JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success
The company has made more than 50 deals for its proprietary technology as it looks forward to a potentially “transformative” year.
Healthcare
Big pharma and investors re-engage in CGTs and race to scale
Investors bet on newer technology and indications for CGTs
Redefining clinical trials in oncology and rare diseases across the Europe
Metagenomi culls 25% of its workforce and replaces CEO in reshuffle
FDA halts uniQure’s plans for Huntington’s disease gene therapy
Sensei to ditch its lead candidate and cut workforce amidst strategic review
FDA gives first approval for recurrent respiratory papillomatosis therapy
